Oct 17, 2022
Paula Brown Stafford is the President, CEO, and Chairman of Novan, which is focused on the research, development, and commercialization of therapies for skin diseases using a novel chemical entity. The first target indication is molluscum contagiosum, a highly contagious viral skin infection caused by molluscipoxvirus with no current FDA-approved treatment.
Paula explains, "The prevalence in the U.S. is around 6 million people, in terms of who gets it. In our clinical trials, which seem to be indicative of the normal population, the average age of the patient is about six and a half, primarily children, one year of age to 14, are the ones who get or are susceptible to this virus."
"Our product candidate is Berdazimer gel 10.3%. It's a topical gel under investigation here at Novan to be a first-in-class therapy for the treatment of molluscum. The active ingredient is Berdazimer sodium, which is a nitric oxide- releasing agent. Our other products potentially for acne, potentially for other areas like psoriasis, et cetera, may have a different percentage number after Berdazimer gel because it refers to the amount of nitric oxide that's in the final product."
@Novan_Biotech #Novan #Dermatology #Molluscum #Pediatrics